A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Eli Lilly and Company
Astellas Pharma Inc
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
Amgen
iOnctura
Merck Sharp & Dohme LLC
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Inhibrx Biosciences, Inc
Pfizer
RemeGen Co., Ltd.
Regeneron Pharmaceuticals
Merck Sharp & Dohme LLC
AstraZeneca
HC Biopharma Inc.
Cullinan Therapeutics Inc.
Merck Sharp & Dohme LLC
Tesaro, Inc.
Amgen
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
BeiGene
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Inspirna, Inc.
Boehringer Ingelheim
Blueprint Medicines Corporation
Innovent Biologics (Suzhou) Co. Ltd.
AstraZeneca
GlaxoSmithKline
Arcus Biosciences, Inc.
Genentech, Inc.
Bristol-Myers Squibb
Jiangsu Hansoh Pharmaceutical Co., Ltd.
MedImmune LLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Cantargia AB
Blueprint Medicines Corporation
Aileron Therapeutics, Inc.
Innovent Biologics (Suzhou) Co. Ltd.
Merck Sharp & Dohme LLC
Novartis
Eli Lilly and Company
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
BioNTech SE
Novartis